Hyperlipidemic drugs

Hypo lipidemic drugs

• Plasma lipids consist mostly of lipoproteins- spherical macromolecular complexes of lipid and specific protein called (apolipoproteins)
• Clinically important lipoproteins in decreasing order of atherogenisity are LDL, VLDL, chylomicrons, and HDL
• The occurrence of IHD, is positively associated with elevate LDL cholesterol in the blood in contrast high level of HDL cholesterol have been associated with decrease risk of heart diseases
• Cholesterol levels may be elevated because of an individual's life style e.g. lack of exercise and consumption of diet containing excess saturated fatty acids
• Hyperlipidemias can also result from inherited a single gene defect in lipoprotein metabolism or more commonly by a combination of genetic and life style factors


The genetic types of hyperlipidemias Is a drug of choice in treatment acute form of angina pectorisit is potent vasodilator ,it relaxes smooth muscles of blood vessels ( on venous side more than arterial side ), lead to decrease in preload and after load on the heart lead to reduce myocardial oxygen and energy demand On venous side lead to decrease venous return to heart, lead to decrease ventricular volume and consequently lead decrease left ventricular diastolic pressure.On arterial side lead to decrease arterial blood pressure lead to reduction ejection time by this decrease heart work and decrease oxygen and energy demand and overcome on the anginal pectoris, beside increase oxygen supply to heart by increase coronary vasodilatation
1-Type one (familial hyper chylomiconemia)
where massive hyperchylomicronemia following normal dietary fat intake due to
deficiency of lipoprotein lipase or deficiency of apolipoprotein C 2 ; this type not
associated with increased risk of IHD
2- Type two a (familial hypercholesterolemia)
elevated LDL with normal VLDL level due to block in LDL degradation, result in
increased serum cholesterol while triacylglycerol (TG) level is normal ,occur due to
defect in synthesis or processing of LDL receptors and this type associated greatly with
increased risk of IHD
3-Type two b (familial combined –mixed- hyperlipidemia)
similar to type 2a, but VLDL is also increased result in elevated serum TG as well as
cholesterol levels caused by overproduction of VLDL by the liver.


Type three (familial dysbeta lipoproteinemia)
associated with increased level of IDL and this
lead to increase serum cholesterol and TG due to
overproduction by liver for IDL or underutilization
Type four (familial hypertriglyceridemia)
result from increase VLDL with normal LDL lead to
increase serum TG with normal or slightly increase
serum cholesterol
Type 5(familial mixed hypertriglyceridemia)
serum VLDL and chylomicron are elevated
LDL is normal or decreased lead to greatly elevated
TG level ,due to over production of VLDL and
chylomicron or decrease clearance

1-HMG-COA reductase inhibitors (Statins)

2-Niacin (nicotinic acid) (vitamin B3)
3-Fibrate e.g. Fenofibrate, Gemfibrozil,
Ciprofibrate and Bezafibrate
4-Bile acid sequestrants or bile acid –binding
resins e.g. Cholestyramine, Colestipol, and
Colesevelam
5- Cholesterol absorption inhibitors e.g. Ezetimibe
Groups of anti hyperlipidemic drugs


1- HMG-COA reductase inhibitors
• Also known as a statins, lower elevated LDL cholesterol level this group of drugs inhibits the first step oh cholesterol synthesis ;
• these drugs are analog of 3-hydroxy -3-methyl glutarate, the precursor of cholesterol ;all compete effectively to inhibit HMG – COA reductase (the rate limiting step in cholesterol synthesis )
• Atorvastatin is the most potent LDL cholesterol –lowing statin drug, followed by pravastatin and Fluvastatin and then Lovastatin and Simvastatin
• This group can increase plasma HDL level in some patients and decrease in triacylglycerol also occur
• Depletion of intracellular cholesterol cause the cell to increase the number of specific cell surface LDL receptors ,thus the end result is a reduction in plasma cholesterol both by inhibit cholesterol synthesis and by increase catabolism of LDL

Clinical uses and Pharmacokinetic

• These drugs are effective in lowing plasma cholesterol levels in all types of hyperlipidemias especially type2a and type 2b

• Given orally, well absorbed from intestine, exposed for extensive first pass metabolism in the liver, excretion take place through the bile with some urinary excretion half-life range from 1.5-2 hrs.

Side effects and drug interaction

Side effects
1-mild GIT upset
2- Abnormal liver functions
3- Myopathy with skin rash

Drug interaction

Statin drugs increase Warfarin level thus it is important to evaluate
prothrombin time frequently


Contraindication
In pregnant women, breast feeding and should not use in children and
teenagers

2- Niacin (Nicotinic acid)

• Can decrease level of LDL by 10-20 % and it is the most effective agent for increasing HDL; Niacin can be sue in combination with statin
Mechanism of action
• Niacin inhibits lipolysis in adipose tissue (the primary producer of circulating free fatty acids) as a major precursor for triacylglycerol synthesis , thus it decreases triacylglycerol synthesis in the liver(which is required for VLDL production),LDL(the cholesterol- rich lipoprotein)is derived from VLDL in the plasma ,therefore, reduction in the VLDL concentration also result in a decrease in the plasma LDL concentration, thus both plasma TG and cholesterol are lowered
Clinical uses
• Lipid- lowering properties require much higher doses than when used as a vitamin, often used in combination with other lipid-lowing agents
1-Sever hypercholesterolemia (all types), often in combination with other lipid lowing drugs
2- It is the most potent lipid lowing agent for raising plasma HDL level

Pharmacokinetic and Side effects of Niacin

Pharmacokinetic
Administered orally converted in the body to
nicotinamide which is incorporated into the cofactor
nicotinamide adenine dinucleotide (NAD), excretion in
urine
Side effects
More common side effect is cutaneous flush and pruritus, intake of Aspirin prior to taking Niacin decrease the flash
sometimes nausea abdominal pain
hyperuricemia and hepatotoxicity have also been reported
to minimize side effects start on low initial dose and gradually increase it and taken with meals


3- Fibrate group
• Fenofibrate and Gemfibrozil are derivative of fibric acid that lower serum TG and increase HDL levels ,both have the same mechanism of action ,but Fenofibrate is more effective than Gemfibrozil in lowing plasma LDL cholesterol and TG levels
Mechanism of action
• Fibrate mediated gene expression lead to decrease triacylglycerol concentration (by increase the expression of lipoprotein lipase and decrease apoC-2 concentration), and increase level of HDL cholesterol (by increase the expression of apo-A-1 and Apo- A-2) that mean
1-activation of lipase which breakdown cholesterol
2- Suppress release of free fatty acid from adipose tissue
3- Inhibit synthesis of TG in the liver
4- Increase secretion of cholesterol in the bile

Clinical uses

The fibrate are used in the treatment of hypertriacylglycermia, causing significant decrease in plasma triacylglycerol levels
Fenofibrate and Gemfibrozil are particularly useful in treating type 3 hyperlipidemia (dysbeta lipoproteinemia) in which IDL accumulated
Patients with hypertriacylglycermia (type 4 elevated VLDL) or type 5 (elevated VLDL+ chylomicron) diseases who don’t respond to diet or other drugs may also benefit from treated with these drugs

Pharmacokinetic and Side effects

Both drugs are completely absorbed after oral dose, both distributed widely in body, bound to albumin, both are undergo extensive hepatic metabolism and are excrete in the urine
Side effects
1-the most common is GIT disturbances
2- Lithiasis (gall stone formation)
3- Myositis and myopathy
4-Prolonged prothrombin time

Drug interaction
Both fibrates compete with the anticoagulant drugs
Contraindication
In pregnancy and lactating women, they should not be use in patients
with severe hepatic and renal dysfunction or in patients with preexisting
gall bladder diseases


4-Bile acid binding resins
Have significant LDL cholesterol –lowing effect, these drugs act by binding to bile acids and bile salts in small intestine, the resin/ bile acid complex is excrete in the feces, this preventing the bile acid from returning to the liver by enterohepatic circulation
Lowing the bile acid concentration causes hepatocytes to increase conversion of cholesterol to bile acids, resulting in a replenished supply of these compounds, consequently the intracellular cholesterol concentration decrease which activate increase hepatic uptake of cholesterol containing LDL lead to a fall in plasma LDL ,the final outcome of this sequence of events is decrease total plasma cholesterol concentration

Clinical uses and side effects

Clinical uses
1-Drugs of choice in treatment type 2a and type two b hyperlipidemia
2- Cholestyramine can also relive pruritus caused by accumulation of bile
acids in patients with biliary obstruction
Pharmacokinetic
These drugs taken orally, because they are insoluble in water and are very large,
they are neither absorbed nor metabolically altered by the intestine, but they are
totally excreted in feces
Side effects
1-GIT disturbances are more common
2- Impaired fat- soluble vitamins (A, D, E, K), especially by Cholestyramine and
Colestipol, but not Colesevelam, patients on long- term therapy may need
supplement fat-soluble vitamins
Drug interaction
Cholestyramine and Colestipol are interfere with the intestinal absorption of many
drugs e.g. Tetracycline, Digoxin, Warfarin, Aspirin, Thiazide diuretic, therefor; drugs
should be taken at least one- two hours before or 4-6 hours after the bile acid-
binding resins


5- Cholesterol absorption inhibitors e.g. Ezetimibe
Selectively inhibits intestinal absorption of dietary and biliary cholesterol in small intestine
it is metabolized in the liver and intestine with biliary and renal excretion, half-life 22 hours
it decreases LDL, TG, and increase HDL, Simvastatin and Ezetimibe in one formulation is more effective than Simvastatin alone